Select Language
Fc gamma RIII / CD16
Fc gamma RIII / CD16 Overview
| English Name | Low affinity immunoglobulin gamma Fc region receptor III-A | Approved Drugs | 0 |
| Drugs in Clinical Trials | 14 | Target Synonym | IGFR3，FCG3，Fc Fragment Of IgG， Low Affinity IIIa， Receptor For (CD16)，Fc Fragment Of IgG， Low Affinity III， Receptor For (CD16)，Immunoglobulin G Fc Receptor III，Fc-Gamma Receptor III-2 (CD 16)，Neutrophil-Specific Antigen NA，Fc-Gamma Receptor IIIb (CD16)，Fc Gamma Receptor III-A，Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment，IgG Fc receptor III-2，Low affinity immunoglobulin gamma Fc region receptor III-A，FCGR3，CD16A，Fc-gamma RIII-alpha，FCGR3A，Fc Fragment Of IgG Receptor IIIa，Fc Fragment Of IgG， Low Affinity IIIa， Receptor (CD16a)，CD16a Antigen，Fc Gamma Receptor IIIa，Fc-Gamma RIIIa，Fc-Gamma RIII，FcgammaRIIIA，FCGRIII，FcRIIIa，FCR-10，FCRIII，IMD20，CD16 |
| Highest Development Stage | Phase 2 Clinical | ||
| English Name | Low affinity immunoglobulin gamma Fc region receptor III-A |
| Target Synonym | IGFR3，FCG3，Fc Fragment Of IgG， Low Affinity IIIa， Receptor For (CD16)，Fc Fragment Of IgG， Low Affinity III， Receptor For (CD16)，Immunoglobulin G Fc Receptor III，Fc-Gamma Receptor III-2 (CD 16)，Neutrophil-Specific Antigen NA，Fc-Gamma Receptor IIIb (CD16)，Fc Gamma Receptor III-A，Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment，IgG Fc receptor III-2，Low affinity immunoglobulin gamma Fc region receptor III-A，FCGR3，CD16A，Fc-gamma RIII-alpha，FCGR3A，Fc Fragment Of IgG Receptor IIIa，Fc Fragment Of IgG， Low Affinity IIIa， Receptor (CD16a)，CD16a Antigen，Fc Gamma Receptor IIIa，Fc-Gamma RIIIa，Fc-Gamma RIII，FcgammaRIIIA，FCGRIII，FcRIIIa，FCR-10，FCRIII，IMD20，CD16 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 14 |
| Highest Development Stage | Phase 2 Clinical |
Fc gamma RIII / CD16 Product List
- Product Category
Protein (5)
- Product Status
Launched (5)
- Species
Mouse (2)Cynomolgus (2)Rhesus macaque (1)
- Tag
His Tag (3)His Tag & Avi Tag (2)
- Conjugate
Unconjugated (3)Biotin-labeled (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT CDA-M52H8 |  Mouse | HEK293 | Mouse Fc gamma RIII / CD16 Protein, His Tag (SPR & MALS verified) |  |  |  |
HOT FC6-C52H9 |  Cynomolgus | HEK293 | Cynomolgus Fc gamma RIII / CD16 Protein, His Tag (MALS & BLI verified) |  | |  |
HOT FC6-C82E0 | Cynomolgus | HEK293 | Biotinylated Cynomolgus Fc gamma RIII / CD16 Protein, His,Avitag™ (MALS & BLI verified) |  | | |
FC6-M82E0 | Mouse | HEK293 | Biotinylated Mouse Fc gamma RIII / CD16 Protein, His,Avitag™ (MALS & SPR verified) |  | | |
FC6-R52H6 |  Rhesus macaque | HEK293 | Rhesus macaque Fc gamma RIII / CD16 Protein, His Tag (SPR & MALS verified) |  | | |
Total: 5
- 1
Fc gamma RIII / CD16 Background
CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.
CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibodydependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.
Fc gamma RIII / CD16 Synonyms
FCGR3
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Acimtamig | AFM-13 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Hodgkin Disease; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Mycosis Fungoides | Details |
| IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms | Details |
| FT-538 | FT-538 | Phase 2 Clinical | Fate Therapeutics Inc | Coronavirus Disease 2019 (COVID-19); Fallopian Tube Neoplasms; HIV Infections; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Respiratory Distress Syndrome, Adult; Solid tumours | Details |
| GMA-161 | GMA-161 | Phase 1 Clinical | Macrogenics Inc, Sanofi | Purpura, Thrombocytopenic, Idiopathic | Details |
| GTB-5550 | GTB-5550; B7H3 TriKE™; cam1615B7H3; GTB-5550 TriKE™ | Phase 1 Clinical | University Of Minnesota | Solid tumours | Details |
| FT-576 | FT-576 | Phase 1 Clinical | Fate Therapeutics Inc, University Of Minnesota | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplasms | Details |
| Donor-derived CD123-CD16 bispecific antibody-modified NK cells therapy(Chinese PLA General Hospital) | Phase 1 Clinical | Pla General Hospital | Leukemia, Myeloid, Acute | Details | |
| GTB-3650 | GTB-3650; GTB-360; OXS-3350; OXS-C3550 | Phase 1 Clinical | Masonic Cancer Center, University Of Minnesota | Bone Marrow Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | Details |
| BGB-B3227 | BGB-B3227 | Phase 1 Clinical | BeOne Medicines (Beijing) Co Ltd | Gastrointestinal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| SM-3321 | SM-3321; SM3321 | Phase 1 Clinical | Zhuhai StarMab BioMed Technology Ltd | Leukemia, Myeloid, Acute; Neoplasms | Details |
| FT-596 | FT-596 | Phase 1 Clinical | Fate Therapeutics Inc | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
| SAR-443579 | SAR-443579; SAR443579; SAR'579; IPH6101; IPH-6101 | Phase 1 Clinical | Sanofi | Blastic Plasmacytoid Dendritic Cell Neoplasm; Hematologic Diseases; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
| FT-516 | FT-516 | Phase 1 Clinical | Fate Therapeutics Inc, University Of Minnesota | Abdominal Neoplasms; Coronavirus Disease 2019 (COVID-19); Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours | Details |
- Overview
- Product List
- Clinical Drug Information
Share to: